Tags

Type your tag names separated by a space and hit enter

Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
J Clin Endocrinol Metab. 1991 May; 72(5):1008-13.JC

Abstract

The effects of the antiandrogen drugs cyproterone acetate (CPA) and spironolactone on hair growth and androgen levels were compared in a randomized study of 48 hirsute women. Twenty six subjects completed 6 months of therapy with 100 mg/day CPA and 19 subjects completed 6 months of 100 mg/day spironolactone. All except 10 subjects received concomitant estrogen therapy. Measured objectively, total hair diameter fell by 17.1% with spironolactone (P less than 0.001), and by 16.8% with CPA (P less than 0.001). The diameter of the hair medulla fell by 17.8% with spironolactone (P less than 0.01), and by 31.7% with CPA (P less than 0.001). There was no difference between the drugs in their effect on hair diameter. Plasma testosterone levels also fell significantly with both drugs. As a subjective assessment of treatment efficacy, the frequency with which subjects performed cosmetic measures was recorded. This fell by 38% with spironolactone and by 44.7% with CPA (P less than 0.001 both drugs), and again there was no difference between the drugs. Side effects caused cessation of treatment in one subject taking CPA and two subjects taking spironolactone, and milder side effects were noted in two further subjects from each treatment group. We conclude that spironolactone and CPA, in the dosages used in this study, are effective and well tolerated agents for the treatment of hirsutism, and that neither drug demonstrates a particular advantage over the other.

Authors+Show Affiliations

O'Brien RC
Department of Endocrinology, Austin Hospital, Heidelberg, Victoria, Australia.
Cooper ME
No affiliation info available
Murray RM
No affiliation info available
Seeman E
No affiliation info available
Thomas AK
No affiliation info available
Jerums G
No affiliation info available

MeSH

AdultAndrogen AntagonistsAndrogensContraceptives, OralCyproteroneCyproterone AcetateDrug Therapy, CombinationEstrogensFemaleHairHirsutismHumansMiddle AgedProspective StudiesSpironolactoneTestosterone

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

1827125

Citation

O'Brien, R C., et al. "Comparison of Sequential Cyproterone Acetate/estrogen Versus Spironolactone/oral Contraceptive in the Treatment of Hirsutism." The Journal of Clinical Endocrinology and Metabolism, vol. 72, no. 5, 1991, pp. 1008-13.
O'Brien RC, Cooper ME, Murray RM, et al. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab. 1991;72(5):1008-13.
O'Brien, R. C., Cooper, M. E., Murray, R. M., Seeman, E., Thomas, A. K., & Jerums, G. (1991). Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. The Journal of Clinical Endocrinology and Metabolism, 72(5), 1008-13.
O'Brien RC, et al. Comparison of Sequential Cyproterone Acetate/estrogen Versus Spironolactone/oral Contraceptive in the Treatment of Hirsutism. J Clin Endocrinol Metab. 1991;72(5):1008-13. PubMed PMID: 1827125.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. AU - O'Brien,R C, AU - Cooper,M E, AU - Murray,R M, AU - Seeman,E, AU - Thomas,A K, AU - Jerums,G, PY - 1991/5/1/pubmed PY - 1991/5/1/medline PY - 1991/5/1/entrez SP - 1008 EP - 13 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 72 IS - 5 N2 - The effects of the antiandrogen drugs cyproterone acetate (CPA) and spironolactone on hair growth and androgen levels were compared in a randomized study of 48 hirsute women. Twenty six subjects completed 6 months of therapy with 100 mg/day CPA and 19 subjects completed 6 months of 100 mg/day spironolactone. All except 10 subjects received concomitant estrogen therapy. Measured objectively, total hair diameter fell by 17.1% with spironolactone (P less than 0.001), and by 16.8% with CPA (P less than 0.001). The diameter of the hair medulla fell by 17.8% with spironolactone (P less than 0.01), and by 31.7% with CPA (P less than 0.001). There was no difference between the drugs in their effect on hair diameter. Plasma testosterone levels also fell significantly with both drugs. As a subjective assessment of treatment efficacy, the frequency with which subjects performed cosmetic measures was recorded. This fell by 38% with spironolactone and by 44.7% with CPA (P less than 0.001 both drugs), and again there was no difference between the drugs. Side effects caused cessation of treatment in one subject taking CPA and two subjects taking spironolactone, and milder side effects were noted in two further subjects from each treatment group. We conclude that spironolactone and CPA, in the dosages used in this study, are effective and well tolerated agents for the treatment of hirsutism, and that neither drug demonstrates a particular advantage over the other. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/1827125/Comparison_of_sequential_cyproterone_acetate/estrogen_versus_spironolactone/oral_contraceptive_in_the_treatment_of_hirsutism_ DB - PRIME DP - Unbound Medicine ER -